
Metastasis is the leading cause of mortality in prostate cancer (PCa), with bone being the most common site of dissemination. The survival of tumor cells in the circulation following detachment from the extracellular matrix (ECM) is an essential prerequisite for cancer metastasis, yet the underlying mechanisms remain incompletely understood. To investigate the cellular adaptations that support survival under ECM-detached conditions, we established detachment-resistant (DR) models using PC-3 and LNCaP cells. COMP expression was examined in PCa clinical tissues and DR cells. Functional and mechanistic studies were then performed both in vitro and in vivo. COMP was highly expressed in PCa tissues and DR PCa cells. COMP upregulation promoted ferroptosis resistance by reducing intracellular Fe²⁺ accumulation and lipid peroxidation, thereby facilitating PCa progression and metastasis. Mechanistically, COMP directly bound to mucin 1 (MUC1) via a high-affinity Arg628-Asp543 salt bridge, which promoted MUC1 phosphorylation and enhanced its signaling activity. p-MUC1 subsequently inhibited the Hippo signaling pathway, promoting nuclear translocation of Yes-associated protein 1 (YAP1). YAP1 cooperated with TEAD transcription factors to drive transcription of nuclear protein 1 (NUPR1), which activated lipocalin-2 (LCN2), an iron-transporting protein that critically regulates intracellular iron homeostasis and redox balance, thereby conferring ferroptosis resistance. Importantly, suppressing COMP significantly inhibited PCa bone and lung metastasis in vivo. This study reveals that COMP facilitates PCa bone metastasis by enhancing ferroptosis resistance through the MUC1/YAP1/NUPR1/LCN2 axis, suggesting that inhibition of COMP combined with ferroptosis activators may represent a promising therapeutic strategy to suppress PCa bone metastasis.
Rhabdomyosarcoma (RMS) is the most common pediatric soft-tissue sarcoma. Despite intensive multimodal therapy, outcomes remain poor for patients with metastatic or recurrent disease, underscoring an urgent need for novel molecularly targeted therapies. We previously identified advillin (AVIL), a gelsolin family actin-binding protein, as a novel oncogenic driver overexpressed in RMS and associated with poor clinical outcomes. However, the downstream molecular mechanisms by which AVIL drives and sustains oncogenic signaling in RMS have remained unclear. Here, we investigated AVIL-dependent regulation of the Hippo pathway effector Yes-associated protein (YAP) and the therapeutic relevance of the AVIL–YAP axis in RMS. AVIL expression was evaluated in clinical RMS specimens across histologic subtypes, tumor grades, and clinical stages. Transcriptomic, molecular, and functional analyses investigated AVIL-dependent YAP regulation in RMS cells, mesenchymal stem cells, and patient-derived models. Therapeutic dependency on the AVIL–YAP signaling axis was assessed using genetic and pharmacologic approaches in vitro and in patient-derived xenograft models. Statistical analyses included unpaired two-tailed t-tests, one-way ANOVA, log-rank (Mantel–Cox) tests, and REML-based mixed-effects models. Nonlinear regression determined IC₅₀ values. AVIL was broadly expressed across RMS specimens spanning stages, grades, and subtypes, and functioned as an upstream regulator of the Hippo effector YAP. AVIL promoted YAP stabilization and nuclear accumulation, enhancing YAP-dependent transcription alongside altered Hippo pathway regulation. Genetic AVIL depletion impaired YAP signaling and RMS cell survival, while promoting myogenic differentiation. Actin perturbation diminished AVIL-associated nuclear YAP, and mutations affecting AVIL actin-regulatory functions attenuated YAP activity and suppressed proliferation and migration, supporting a role for actin remodeling in AVIL-driven tumorigenesis. AVIL-high RMS models showed heightened sensitivity to YAP inhibition in vitro, whereas AVIL-depleted cells showed diminished responsiveness. Pharmacologic YAP inhibition suppressed YAP-dependent transcription in vitro and reduced tumor incidence in AVIL-high RMS xenografts in vivo. Our findings identify a previously unrecognized AVIL–YAP axis that sustains oncogenic transcription and tumorigenic phenotypes in RMS. These results establish AVIL-mediated YAP dependency as a therapeutically actionable vulnerability and support targeting this pathway as a treatment strategy for aggressive RMS.
Risk stratification in classical Hodgkin lymphoma (cHL) primarily relies on clinical and radiologic parameters, but outcomes are still heterogeneous after standard first-line chemotherapy. We investigated how, the spatial interplay between Hodgkin and Reed–Sternberg cells (HRS) and tumor microenvironment (TME) at diagnosis, impacts on clinical aggressiveness. Spatial transcriptomics was performed to profile HRS (CD30+), non-tumoral B cells (CD20+) and TME (CD45+/CD30-) in a matched series of cHLs, comparing 4 relapsed/refractory (R/R+) and 4 relapse-free (R/R-) patients. A retrospective monocentric training cohort (N = 155) and a multicentric retrospective validation cohort (N = 89) of cHLs were analyzed using digital barcoding-based gene-expression profiling of 770 immune-related genes, to derive and validate a biologically relevant gene score predictive of progression-free survival (PFS). A B-cell–related gene score (B-score) was developed using elastic net regression. Spatial transcriptomics showed that R/R+ cHLs exhibited loss of B-cell lineage identity in HRS cells and marked depletion of naïve B cells in TME. Digital barcoding transcriptomic analysis in the training cohort (4-year PFS 80.4